KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Neogenomics (NEO) EBT Margin: 2009-2025

Historic EBT Margin for Neogenomics (NEO) over the last 17 years, with Sep 2025 value amounting to -14.05%.

  • Neogenomics' EBT Margin fell 342.00% to -14.05% in Q3 2025 from the same period last year, while for Sep 2025 it was -16.07%, marking a year-over-year decrease of 368.00%. This contributed to the annual value of -12.21% for FY2024, which is 420.00% up from last year.
  • According to the latest figures from Q3 2025, Neogenomics' EBT Margin is -14.05%, which was up 44.39% from -25.27% recorded in Q2 2025.
  • Neogenomics' 5-year EBT Margin high stood at 60.33% for Q2 2021, and its period low was -45.37% during Q1 2022.
  • Its 3-year average for EBT Margin is -15.50%, with a median of -14.12% in 2023.
  • As far as peak fluctuations go, Neogenomics' EBT Margin skyrocketed by 8,097bps in 2021, and later tumbled by 9,314bps in 2022.
  • Quarterly analysis of 5 years shows Neogenomics' EBT Margin stood at -35.16% in 2021, then skyrocketed by 1,676bps to -18.40% in 2022, then surged by 857bps to -9.83% in 2023, then surged by 45bps to -9.38% in 2024, then plummeted by 342bps to -14.05% in 2025.
  • Its EBT Margin was -14.05% in Q3 2025, compared to -25.27% in Q2 2025 and -15.27% in Q1 2025.